Ацетилсаліцилова кислота в кардіологічній практиці: фокус на ентеротоксичність
DOI:
https://doi.org/10.30978/UTJ2018-3-4-79Ключові слова:
ацетилсаліцилова кислота, клопідогрель, ентеропатія, ентеротоксичність, гастропатіяАнотація
Ацетилсаліцилова кислота (АСК) є одним з найчастіше призначуваних препаратів у світі. Постійний прийом АСК має суттєві побічні ефекти, у тому числі з боку шлунково-кишкового тракту. В огляді, присвяченому ентеротоксичному впливу АСК, викладено сучасні погляди на застосування дезагрегантної терапії, а також висвітлено уявлення щодо частоти, патогенезу та підходів до лікування АСК-асоційованих ентеропатій.Посилання
Gubskaya EYu. Novyy diagnoz mikroskopicheskiy enterit: opredeleniye, sovremennyye podkhody k diagnostike, differentsial'noy diagnostike i lecheniyu. Sovremennaya gastroenterologiya. 2016;3:120-126.
Kushnir SM. Terapevtychna efektyvnist atsetilsalitsilovoyi kysloty pry sertsevosudynna zakhvoryuvannyakh. Zhurn Arterialna hipertenziya. 2012;2 (22).
Shcherbatykh YeV, Kalyagin AN, Shcherbatykh AV. NPVPassotsiirovannaya patologiya organov pishchevareniya. Sib med zhurn (Irkutsk). 2007;7:23-27.
Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting. Canadian J Сardiol. 2011;27 (3):S1-S59.
Bjarnason I, et al. Effect of nonsteroidal anti-inflammatory drugs on the human small intestine. Drugs. 1986;32(1):35-41.
Bjarnason I, et al. Metronidazole reduces intestinal inflammation and blood loss in nonsteroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33 (9):1204-1208.
Bjarnason I, Hayllar J. Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterol. 1993;104(6):1832-1847.
Boelsterli UА, RamirezAlcantara V. NSAID acyl glucuronides and enteropathy. Curr. Drug Metab. 2011;12 (3):245-252.
Chan FKL, Lau JYW. Peptic ulcer disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA. Elsevier Saunders; 2016.
Chen WC, Lin KH, Huang YT, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 1201;457(2):1542-1550.
Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer A Decision Analysis: Technical Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). 2015 Report N 1505229EF1. https://www.ncbi.nlm.nih.gov/books/NBK321651.
Endo H, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44(6):544.
Endo H, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46(7):894-905.
Endo H, et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion. 2009;79(1):44-51.
Endo H, et al. Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? J. Gastroenterol. 2017;52(2):194-202.
Fujimori S, et al. Prevention of nonsteroidal anti-inflammatory drug–induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointestinal Endoscopy. 2009;69(7):1339-1346.
Iwamoto J, et al. Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding. World J Gastroenterol. 2014;20(36):13133-13138. doi:10.3748/wjg.v20.i36.13133.
Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969;54(2):237.
Lambert M. AHA/ASA guidelines on prevention of recurrent stroke. Am Fam Physician. 2011;83(8):993-1001.
Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):7-28.
Leung JW, et al. Expression of bacterial β-glucuronidase in human bile: an in vitro study. Gastrointestinal Endoscopy. 2001;54(3):346-350.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):10821115. doi:10.1016/j.jacc.2016.03.513.
Maiden L, et al. Longterm effects of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5(9):1040-1045.
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Failure. 2012;14(8):803-869.
Mizukami K, et al. Aspirininduced small bowel injuries and the preventive effect of rebamipide. World J. Gastroenterology. 2011;17 (46):5117-5122. doi: 10.3748/wjg.v17.i46.5117.
Montalto M, et al. Clinical trial: the effects of a probiotic mixture on nonsteroidal anti-inflammatory drug enteropathya randomized, double-blind, crossover, placebo-controlled study. Aliment Pharmacol Ther. 2010;32(2):209-214. doi:10.1111/j.13652036.2010.04324.x.
Muraki M, et al. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic nonsteroidal antiinflammatory drug users. Scand J Gastroenterol. 2014;49(3):267273.
Otani K, et al. Microbiota Plays a Key Role in Non-Steroidal AntiInflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28.
Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterol. 1997;112(1):109-117.
Schmassmann A, et al. Effects of inhibition of prostaglandin endoperoxide synthase2 in chronic gastrointestinal ulcer models in rats. Br J Pharmacol. 1998;123(5):795-804.
Shinomura Y. New Trends and Techniques in Gastroenterology. Digestion. 2017;95(1):5.
Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43(8):581-588.
Shiotani A, et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose entericcoated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol. 2010;45(3):292-298.
Srinivasan A, De Cruz P. А practical approach to the clinical management of NSAID enteropathy. Scand J Gastroenterol. 2017;52(9):941-947. doi10.1080/00365521.2017.1335769.
Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Ann Intern Med. 2009;150(6):379-386.
Truong C. Low-dose acetyl-salicylic acid for primary prevention of cardiovascular disease. Can Fam Physician. 2015;61(11):971-975.
Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19(12):1861-1876. doi:10.3748/wjg.v19.i12.1861.
Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012;165(1):67-74.
Watanabe T, et al. A multi-center, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for lowdose aspirin-induced moderate-to-severe small intestinal damage. PloS One. 2015;10(4):e0122330.
Watanabe T, et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr. 2011;48(2):117-121.
